A subsidiary of Jianfeng Group (600668.SH) received a notice of approval for the marketing application of the chemical raw drug methyldopa

Zhitongcaijing · 1d ago

Zhitong Finance App News, Jianfeng Group (600668.SH) issued an announcement. Recently, Anhui Jianfeng Beika Pharmaceutical Co., Ltd. (“Jianfeng North Carolina”), a subsidiary of the company, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” (Notice Number: 2026YS00812) from the State Drug Administration regarding the chemical ingredient methyldopa.

Methyldopa (Methyldopa) was developed by MSD (MSD, Merck Sharp & Dohme), approved and marketed by the FDA in 1962. It is the world's first generation central antihypertensive drug. As a precursor drug, methyldopa passes through the blood-brain barrier and is metabolized centrally to produce α-methylnorepinephrine (pseudoneurotransmitter), stimulates central brainstem α2 receptors, inhibits sympathetic impulses, reduces peripheral vascular resistance, and achieves hypotension. It is the classic drug of choice for hypertension during pregnancy.